1-7 of 7
Daniel T. Peters
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I. Ravikumar, Jad Othman, Jenny O’Nions, Daniel T. Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard Dillon, Joshua F. Zeidner, Daniel A. Pollyea
Journal: Blood
Blood (2024) 144 (26): 2788–2792.
https://doi.org/10.1182/blood.2024026925
Published: 2024
Includes: Supplemental data
Journal Articles

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

Curtis A Lachowiez, Joshua F Zeidner, Ashley M. Eckel, Daniel T Peters, Jacob Fang, Amenech Ashango, Andy Kaempf, Fangyan Dai, Christopher A. Eide, Stephen E. Kurtz, Theodore P Braun, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Daniel A Pollyea
Journal: Blood
Blood (2024) 144 (Supplement 1): 62.
https://doi.org/10.1182/blood-2024-201532
Published: 2024
Journal Articles

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Daniel T Peters, Deedra Nicolet, Yazan F Madanat, Jesus D Gonzalez-Lugo, Alexander J. Ambinder, Onyee Chan, Michael Jamie Hochman, Najla H. Al Ali, Victoria Klein, Krzysztof Mrózek, Tara L. Lin, Alice Mims, Charles Foucar, Joshua F Zeidner
Journal: Blood
Blood (2024) 144 (Supplement 1): 324.
https://doi.org/10.1182/blood-2024-193667
Published: 2024
Journal Articles

Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study

Daniel T Peters, Coco Chang, Anson Snow, Kaitlyn M. Buhlinger, Bianka Patel, Taylor Dennison, Stephanie Dawson, Sean Gallagher, Robyn Tolley, Angela Nichols, Daniel R. Richardson, Anastasia Ivanova, Paul Armistead, Joshua F Zeidner
Journal: Blood
Blood (2024) 144 (Supplement 1): 1481.
https://doi.org/10.1182/blood-2024-193668
Published: 2024
Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz
Journal: Blood
Blood (2024) 144 (Supplement 1): 4314.
https://doi.org/10.1182/blood-2024-202118
Published: 2024
Journal Articles

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Daniel T Peters, Jacob Amburn, Sascha Tuchman, Eben I Lichtman, Christopher Edward Jensen, Koyal Jain, Suzanne Lentzsch, Rajshekhar Chakraborty, Divaya Bhutani, Samuel M Rubinstein
Journal: Blood
Blood (2023) 142 (Supplement 1): 2027.
https://doi.org/10.1182/blood-2023-189341
Published: 2023
Journal Articles

Frontline Azacitidine As a Bridge to Allogeneic Transplantation in Acute Myeloid Leukemia

Michael Richard Grunwald, MD, Michael Keith Allister Zimmerman, MS, Danielle Boselli, MS, Lauren M. Bohannon, Myra M Robinson, MSPH, Daniel T. Peters, Jing Ai, MD PhD, Thomas G. Knight, MD, Jigar Trivedi, MSc, PharmD, Dragos Plesca, PharmD, James T Symanowski, PhD, Edward A Copelan, MD, Jonathan M. Gerber, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3864.
https://doi.org/10.1182/blood.V130.Suppl_1.3864.3864
Published: 2017